Pignataro's ION Plans to Invest in Azimut-Backed Italian Fintech
Andrea Pignataro's ION Group plans to buy a minority stake in a new Italian digital bank backed by private equity firm FSI SGR SpA and asset manager Azimut Holding SpA, according to people familiar with the matter.
Pignataro's ION is set to take a roughly 6% stake in the venture, known as TNB, the people said, asking not to be identified discussing private information. Talks are ongoing and the size of the holding could still change, according to the people.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Report: Wirtz successfully completes medical checks with Liverpool
Germany's Florian Wirtz (L) and France's Manu Kone stand on the pitch after the UEFA Nations League soccer match between Germany and France at Stuttgart Arena. Federico Gambarini/dpa Bayer Leverkusen playmaker Florian Wirtz has successfully completed medical checks with Liverpool, broadcasters Sky reported on Friday. He's now expected to sign a deal with the Premier League champions until 2030. Advertisement The deal for the young forward could be worth up to €150 million ($172.74 million) including bonuses, making Wirtz the most expensive signing in Bundesliga and Premier League history. Only Paris Saint-German's moves for Neymar and Kylian Mbappe have ever carried a higher transfer fee. The Germany international had been a major target for top European clubs, including Leverkusen's Bundesliga rivals Bayern Munich.
Yahoo
33 minutes ago
- Yahoo
Public companies account for 71% of Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ownership, while individual investors account for 19%
The considerable ownership by public companies in Gyre Therapeutics indicates that they collectively have a greater say in management and business strategy 71% of the company is held by a single shareholder (GNI Group Ltd.) Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. If you want to know who really controls Gyre Therapeutics, Inc. (NASDAQ:GYRE), then you'll have to look at the makeup of its share registry. With 71% stake, public companies possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk). Individual investors, on the other hand, account for 19% of the company's stockholders. In the chart below, we zoom in on the different ownership groups of Gyre Therapeutics. See our latest analysis for Gyre Therapeutics Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. Institutions have a very small stake in Gyre Therapeutics. That indicates that the company is on the radar of some funds, but it isn't particularly popular with professional investors at the moment. If the business gets stronger from here, we could see a situation where more institutions are keen to buy. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too. We note that hedge funds don't have a meaningful investment in Gyre Therapeutics. GNI Group Ltd. is currently the largest shareholder, with 71% of shares outstanding. This implies that they have majority interest control of the future of the company. Meanwhile, the second and third largest shareholders, hold 3.1% and 3.1%, of the shares outstanding, respectively. Songjiang Ma, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. We can see that insiders own shares in Gyre Therapeutics, Inc.. In their own names, insiders own US$53m worth of stock in the US$755m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying. The general public, who are usually individual investors, hold a 19% stake in Gyre Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. It appears to us that public companies own 71% of Gyre Therapeutics. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership. It's always worth thinking about the different groups who own shares in a company. But to understand Gyre Therapeutics better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Gyre Therapeutics (of which 1 makes us a bit uncomfortable!) you should know about. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
37 minutes ago
- Yahoo
Gold prices slip as Trump sets two-week deadline over Iran-Israel conflict involvement
Gold prices slumped in early European trading on Friday morning, after US president Donald Trump set a two-week deadline to decide on whether the US would get directly involved in the Iran-Israel conflict. In a briefing on Thursday, White House press secretary Karoline Leavitt read a message from Trump: "Based on the fact that there's a substantial chance of negotiations that may or may not take place with Iran in the near future, I will make my decision whether or not to go within the next two weeks." This provided some relief to investors who were concerned about the potential for more immediate US involvement in the conflict. Foreign ministers from UK, France and Germany are due to hold talks with Iranian officials in Geneva later on Friday to discuss Iran's nuclear programme. Read more: FTSE 100 LIVE: Markets upbeat as UK and EU begin talks on Iran and Trump sets two week deadline European stocks opened higher on Friday morning, on the back of Trump's two-week pause. Meanwhile, gold prices fell, signalling that investors had become less risk averse, as the precious metal is considered to act as a safe haven asset amid political and economic uncertainty. Gold futures (GC=F) were down 1.3% at $3,363.10 an ounce at the time of writing, while the spot gold price fell 0.7% to $3,348.84 per ounce. Neil Wilson, UK investor strategist at Saxo Markets, said: "Some temporary relief but not enough for anyone to hang their hats on properly as the situation remains way too unpredictable. "Base case has started to shift in the direction of direct US involvement, which opens up a pandora's box of mess, but markets seem to be clinging to expectation that it all remains contained like it has in the past. The meeting today is material and could shift the needle — stay sharp." Oil prices rose on Friday morning, trading at six-month highs, as investors assessed the latest developments around the Iran-Israel conflict. Brent crude futures (BZ=F) advanced 0.4% to $77 a barrel, at the time of writing, while West Texas Intermediate futures (CL=F) climbed 0.7% to trade at $75.66 a barrel. Stocks: Create your watchlist and portfolio Oil prices have surged over the past week, driven higher by concerns that the escalating conflict could lead to a disruption of global supply. There is particular focus on the Strait of Hormuz, off the coast of Iran, with around a fifth of global supplies passing through this channel. Derren Nathan, head of equity research at Hargreaves Lansdown, said: "For now, Iranian oil exports look to be unaffected with a report by Kpler suggesting tanker loadings had reached 2.2 million barrels per day so far this week, a five-week high. "Price support looks firm on the demand side after US crude inventories plummeted by 10.1 million barrels compared to a forecasted fall of just 0.6 million." The pound edged higher 0.1% against the dollar (GBPUSD=X) on Friday, trading at $1.3472 at the time of writing, helped by weakness in the greenback. The US dollar index ( which tracks the greenback against a basket of six currencies, fell 0.3% to 98.66. The muted currency moves came as investors weighed the latest UK economic data releases. Data published on Friday showed that UK government borrowing rose to £17.7bn in May, which was up from £17bn a year earlier. Danni Hewson, head of financial analysis at AJ Bell (AJB.L), said: "May's borrowing came in at the highest ever for the month outside of the pandemic and will only add to speculation that the chancellor will have to announce more spending cuts or further tax increases at the next budget if she wants to meet her fiscal rules and pay for her spending plans." Read more: Why bitcoin and gold are rallying as bond yields hit 30-year highs Separate data, also released on Friday, showed that UK retail sales slumped 2.7% in May, which was much lower than the average forecast of a 0.5% fall in a Reuters poll. "How much people are prepared to spend in the shops is a good indication of how confident consumers are feeling, or not, about their personal finances," said Hewson. 'It's interesting that on the day the latest the latest GfK survey suggests people were feeling a little less nervous in May after April's bill hikes, retail figures show sales in the same period were significantly down." In other currency moves, the pound was little changed against the euro (GBPEUR=X), trading at €1.1704 at the time of writing. More broadly, the UK's FTSE 100 (^FTSE) rose 0.5% to 8,838 points at the time of writing. For more details, on broader market movements check our live coverage here. Read more: Looming petrol price increase could hit fragile consumer confidence Bank of England holds interest rates at 4.25% amid inflation fears Eurozone inflation falls below ECB target to 1.9%
